Sinovac Biotech is developing a potential coronavirus vaccine. Photo: Ralf Liebhold/Shutterstock
Brazil’s National Health Surveillance Agency (Anvisa) has concluded its first day of inspections at Chinese pharmaceutical giant Sinovac Biotech’s coronavirus vaccine production facility.
The first step of the process is to check Sinovac’s quality control systems, as well as risk and data management processes, and the validation master plan.
Sinovac is producing the CoronaVac, a potential vaccine being tested in Brazil by the São Paulo state government. Observers fear that regulatory processes could be contaminated by political disputes between São Paulo Governor João Doria and President Jair Bolsonaro — under whom Anvisa operates.
The president has challenged the safety of the CoronaVac on multiple occasions, and went as far as celebrating the suicide of a volunteer that led to the temporary suspension of clinical trials of the Chinese-made vaccine earlier in November.
Support this coverage →The city of Rio de Janeiro estimates that a Madonna concert this Saturday on Copacabana…
Latin America’s trend of banning opposition candidates from elections has caught on in an ever-growing…
The São Paulo City Council on Thursday approved legislation authorizing Brazil’s largest city to sign…
The preliminary report on AI regulations presented to Brazil’s Senate last week provides a middle-of-the-road…
In 2000, Formula 1 great Michael Schumacher had just racked up his 41st race win,…
Overall, the worldwide economic outlook has improved according to the Organization for Economic Co-operation and…